Chris I am beginning to agree "it is very possi
Post# of 30070
Posted On: 09/20/2014 7:48:10 AM
Chris I am beginning to agree
It could also be the same for PhenoGuard as well...
All that said, and on the off-beat chance that I will be severly ostracized on this thread and likely have this post censored, IMHO we do not have a JV Agreement with any BP on Lympro - furthermore, we never did.
I believe that it was and still is Geralds intent on monetizing / selling / exiting and/or spinning off LymPro - and quite possibly, the entire Diagnostics Division - so as to concentrate on MANF exclusively....
http://investorshangout.com/post/view?id=2033852
Predictions of what a BP JV Agreement downpayment are directly tied to the new buzz word - EXIT - which means LymPro is generating revenues - and right now, as the prior post above indicates, there is a time consuming matrix of events which clearly must happen, long before any type of revenue recognition can begin to hit the books.
Also, IMHO this is a longer term play than I think some of us have thought - including myself. IMHO, Amarantus has also demonstrated a 'Walled Garden' style of growth - and I wholeheartedly believe that the additional 1-Bil. AS supports my theory, as the runway has diminished under the current 1-Bil. AS. for the huge amount of costs that will be associated with bringing MANF to market. Just maybe the intent is to have a revenue generating pipeline of Diagnostics with the crown jewel being LymPro in order to additionally fund MANF's go-to-market strategy and off-set the 2nd 1-Bil. AS
Quote:
"it is very possible MANF could see a major partner before Lympro"
It could also be the same for PhenoGuard as well...
All that said, and on the off-beat chance that I will be severly ostracized on this thread and likely have this post censored, IMHO we do not have a JV Agreement with any BP on Lympro - furthermore, we never did.
I believe that it was and still is Geralds intent on monetizing / selling / exiting and/or spinning off LymPro - and quite possibly, the entire Diagnostics Division - so as to concentrate on MANF exclusively....
http://investorshangout.com/post/view?id=2033852
Predictions of what a BP JV Agreement downpayment are directly tied to the new buzz word - EXIT - which means LymPro is generating revenues - and right now, as the prior post above indicates, there is a time consuming matrix of events which clearly must happen, long before any type of revenue recognition can begin to hit the books.
Also, IMHO this is a longer term play than I think some of us have thought - including myself. IMHO, Amarantus has also demonstrated a 'Walled Garden' style of growth - and I wholeheartedly believe that the additional 1-Bil. AS supports my theory, as the runway has diminished under the current 1-Bil. AS. for the huge amount of costs that will be associated with bringing MANF to market. Just maybe the intent is to have a revenue generating pipeline of Diagnostics with the crown jewel being LymPro in order to additionally fund MANF's go-to-market strategy and off-set the 2nd 1-Bil. AS
(0)
(0)